Literature DB >> 10195071

Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis.

J Hull1, A H Thomson.   

Abstract

BACKGROUND: Disease severity in patients with cystic fibrosis shows marked variability. Attempts to explain this phenotypic heterogeneity on the basis of CFTR genotype have had limited success. A study was undertaken to test the hypothesis that naturally occurring variants of the pro-inflammatory cytokine tumour necrosis factor alpha (TNF-alpha) and the detoxifying enzyme glutathione S-transferase M1 (GSTM1) could influence disease severity in cystic fibrosis.
METHODS: Fifty-three children with cystic fibrosis were studied. To allow for the effect of age, all clinical details were collected during the eighth year of age. The subjects were divided into groups, both according to the presence or absence of the TNF2 TNF-alpha -308 promoter polymorphism (n = 20), and by homozygosity for the null allele of GSTM1 (n = 26).
RESULTS: Percentage predicted forced expiratory volume in one second (FEV1) and weight z scores were significantly lower in the TNF2 group (mean difference (95% confidence intervals) for FEV1 11.6% (1.7 to 21.5) and 0.59 (0.06 to 1.12) for weight z score). The Chrispin-Norman chest radiographic score was significantly higher and the Shwachman score was significantly lower in patients homozygous for the GSTM1 null allele.
CONCLUSIONS: Two independent genetic factors have been identified which appear to influence disease severity in cystic fibrosis. These results support the contention that inflammation in cystic fibrosis contributes to tissue damage. Isolation of further such factors may lead to identification of patients at risk of more severe disease and allow targeted aggressive therapy in this group.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10195071      PMCID: PMC1745152          DOI: 10.1136/thx.53.12.1018

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  31 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

2.  The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508).

Authors:  E Kerem; M Corey; B S Kerem; J Rommens; D Markiewicz; H Levison; L C Tsui; P Durie
Journal:  N Engl J Med       Date:  1990-11-29       Impact factor: 91.245

3.  Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer.

Authors:  D J Harrison; A M Cantlay; F Rae; D Lamb; C A Smith
Journal:  Hum Exp Toxicol       Date:  1997-07       Impact factor: 2.903

Review 4.  Detoxication enzymes and chemoprevention.

Authors:  J Wilkinson; M L Clapper
Journal:  Proc Soc Exp Biol Med       Date:  1997-11

5.  The systematic evaluation of the chest radiograph in cystic fibrosis.

Authors:  A R Chrispin; A P Norman
Journal:  Pediatr Radiol       Date:  1974

6.  Peculiarities of the GSTM1 0/0 genotype in French heavy smokers with various types of chronic bronchitis.

Authors:  H Baranova; J Perriot; E Albuisson; T Ivaschenko; V S Baranov; B Hemery; P Mouraire; N Riol; P Malet
Journal:  Hum Genet       Date:  1997-06       Impact factor: 4.132

7.  The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription.

Authors:  K M Kroeger; K S Carville; L J Abraham
Journal:  Mol Immunol       Date:  1997-04       Impact factor: 4.407

8.  Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion.

Authors:  J Seidegård; W R Vorachek; R W Pero; W R Pearson
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

9.  Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis.

Authors:  S L Huang; C H Su; S C Chang
Journal:  Am J Respir Crit Care Med       Date:  1997-11       Impact factor: 21.405

10.  The TNF-alpha gene Nco I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels.

Authors:  J M Fernández-Real; C Gutierrez; W Ricart; R Casamitjana; M Fernández-Castañer; J Vendrell; C Richart; J Soler
Journal:  Diabetes       Date:  1997-09       Impact factor: 9.461

View more
  36 in total

1.  Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study.

Authors:  M Gabolde; M Guilloud-Bataille; J Feingold; C Besmond
Journal:  BMJ       Date:  1999-10-30

2.  The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis.

Authors:  M Gabolde; D Hubert; M Guilloud-Bataille; C Lenaerts; J Feingold; C Besmond
Journal:  J Med Genet       Date:  2001-05       Impact factor: 6.318

Review 3.  Atypical cystic fibrosis--diagnostic and management dilemmas.

Authors:  Colin Wallis
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

Review 4.  Cystic fibrosis modifier genes.

Authors:  Jane Davies; Eric Alton; Uta Griesenbach
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

5.  TNF-alpha promoter polymorphism in relation to TNF-alpha production and clinical status in cystic fibrosis.

Authors:  Sabina Schmitt-Grohé; Frank Stüber; Malte Book; Joachim Bargon; Thomas O Wagner; Christian Naujoks; Ralf Schubert; Michael J Lentze; Stefan Zielen
Journal:  Lung       Date:  2006 Mar-Apr       Impact factor: 2.584

Review 6.  Strategies for identifying modifier genes in cystic fibrosis.

Authors:  Michael P Boyle
Journal:  Proc Am Thorac Soc       Date:  2007-01

Review 7.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

8.  Missense variants in CFTR nucleotide-binding domains predict quantitative phenotypes associated with cystic fibrosis disease severity.

Authors:  David L Masica; Patrick R Sosnay; Karen S Raraigh; Garry R Cutting; Rachel Karchin
Journal:  Hum Mol Genet       Date:  2014-12-08       Impact factor: 6.150

Review 9.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

10.  Modulation of cystic fibrosis lung disease by variants in interleukin-8.

Authors:  A D Hillian; D Londono; J M Dunn; K A B Goddard; R G Pace; M R Knowles; M L Drumm
Journal:  Genes Immun       Date:  2008-06-19       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.